Nanologica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Nanologica şirketinin toplam hissedar öz sermayesi SEK-8.8M ve toplam borcu SEK24.0K olup, bu da borç-öz sermaye oranını -0.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK95.1M ve SEK104.0M dir.

Anahtar bilgiler

-0.3%

Borç/özkaynak oranı

SEK 24.00k

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 4.09m
Eşitlik	-SEK 8.84m
Toplam yükümlülükler	SEK 103.96m
Toplam varlıklar	SEK 95.12m

Son finansal sağlık güncellemeleri

Recent updates

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Oct 10

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Jun 12

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Oct 20

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Jun 23

Is Nanologica (NGM:NICA) A Risky Investment?

Jan 03

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

Jun 14

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Feb 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NICA negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: NICA şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NICA negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: NICA 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NICA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: NICA un, serbest nakit akışı her yıl % 18 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Nanologica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

Is Nanologica (NGM:NICA) A Risky Investment?

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

Recent updates

Nanologica AB (publ), Annual General Meeting, May 22, 2025

Third quarter 2024 earnings released: kr0.54 loss per share (vs kr0.32 loss in 3Q 2023)

New major risk - Market cap size

Nanologica AB (Publ) Elects Alexandra Blomberg Montgomery as New Member of the Board of Directors

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: kr0.25 loss per share (vs kr0.41 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: kr0.46 loss per share (vs kr0.34 loss in 1Q 2023)

Nanologica AB (publ) Announces Chief Operating Officer Changes

New minor risk - Shareholder dilution

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Price target decreased by 25% to kr12.00

Full year 2023 earnings released: kr2.08 loss per share (vs kr1.84 loss in FY 2022)

Nanologica AB (publ) to Report Q2, 2024 Results on Jul 05, 2024

Insufficient new directors

New minor risk - Share price stability

Nanologica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 54.2 million.

New major risk - Financial position

Third quarter 2023 earnings released: kr0.32 loss per share (vs kr0.39 loss in 3Q 2022)

Nanologica AB (publ), Annual General Meeting, May 16, 2024

Nanologica AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

New minor risk - Financial position

Second quarter 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in 2Q 2022)

Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?

Chief Scientific Officer, Gary Pitcairn Will Leave Nanologica AB (publ)

First quarter 2023 earnings released: kr0.34 loss per share (vs kr0.56 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

No longer forecast to breakeven

Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Nanologica (STO:NICA) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr16.50

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Nanologica (NGM:NICA) A Risky Investment?

No longer forecast to breakeven

Third quarter 2021 earnings released: kr0.45 loss per share (vs kr0.32 loss in 3Q 2020)

Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?

First quarter 2021 earnings released: kr0.28 loss per share (vs kr0.40 loss in 1Q 2020)

Full year 2020 earnings released: kr0.80 loss per share (vs kr1.18 loss in FY 2019)

Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%

Nanologica Recruits PK Dutta as SVP Sales and Senior Advisor for Chromatography

New 90-day high: kr15.30

Nanologica AB (publ) Signs Collaboration Agreement with Zentiva for the Use of Nlab Drug Delivery Platforms

New 90-day high: kr13.80

Nanologica AB Engages Scientific Advisors Within Inhalation

Nanologica AB (Publ) Delivers Test Material from Large Scale Production

Nanologica AB (publ) to Report Q3, 2020 Results on Oct 30, 2020

New 90-day high: kr15.05

First half earnings released

New 90-day high - kr14.00

Nanologica AB (publ) to Report Q2, 2020 Results on Aug 21, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin